Shares in Intersect ENT (NSDQ:XENT) rose today after the medical device maker topped expectations on Wall Street with its fourth quarter and full-year financial results.
The Menlo Park, Calif.-based company posted a net loss of -$3.2 million, or-11¢ per share, on sales of $29.5 million for the three months ended Dec. 31, for sales growth of 22% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT posts Street-beating Q4, full-year sales, earnings appeared first on MassDevice.